发明名称 |
Compositions and methods to enhance the immune system |
摘要 |
The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha. |
申请公布号 |
US9352037(B2) |
申请公布日期 |
2016.05.31 |
申请号 |
US201414153714 |
申请日期 |
2014.01.13 |
申请人 |
STICHTING SANQUIN BLOEDVOORZIENING |
发明人 |
van den Berg Timo Kars |
分类号 |
A61K39/395;A61K39/275;C07K16/30;A61K39/12;C07K16/28;A61K39/00 |
主分类号 |
A61K39/395 |
代理机构 |
Hoffmann & Baron, LLP |
代理人 |
Hoffmann & Baron, LLP |
主权项 |
1. A composition comprising
(i) a therapeutic compound that can trigger a host's immune effector cells against a cancer cell, wherein said therapeutic compound is a therapeutic antibody comprising a human or non-human primate IgG Fc portion, wherein the therapeutic antibody induces antibody-dependent cellular cytotoxicity (ADCC), and wherein the therapeutic antibody is selected from the group consisting of rituximab, herceptin, trastuzumab, alemtuzumab, bevacizumab, cetuximab and panitumumab, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPα, wherein said agent is an anti-CD47 antibody or an anti-SIRPα antibody or a Fab fragment, a F(ab′)2 fragment or a scFv fragment thereof. |
地址 |
Amsterdam NL |